Detail akcie Photocure online

Business Summary: Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Photocure ASA revenues increased 11% to NOK118M. Net loss applicable to common stockholders decreased 33% to NOK7.9M. Revenues reflect Europe Hexvix segment increase of 9% to NOK69.3M, Hexvix/Cysview Own Sales segment increase of 13% to NOK47.5M. Lower net loss reflects Other operating expenses decrease of 4% to NOK22.5M (expense), Financial income increase of 12% to NOK6.5M (income).